These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 12173335

  • 1. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G, Scagliotti GV, Torri V, Novello S, Leonardo E, Cappia S, Mossetti C, Ardissone F, Lausi P, Borasio P.
    Cancer; 2002 May 15; 94(10):2669-74. PubMed ID: 12173335
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF.
    Hum Pathol; 2002 Jan 15; 33(1):105-10. PubMed ID: 11823980
    [Abstract] [Full Text] [Related]

  • 3. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.
    Tumori; 2008 Jan 15; 94(3):398-405. PubMed ID: 18705409
    [Abstract] [Full Text] [Related]

  • 4. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
    Saji H, Tsuboi M, Yoshida K, Kato Y, Nomura M, Matsubayashi J, Nagao T, Kakihana M, Usuda J, Kajiwara N, Ohira T, Ikeda N.
    J Thorac Oncol; 2011 Nov 15; 6(11):1865-71. PubMed ID: 21964529
    [Abstract] [Full Text] [Related]

  • 5. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G, Del Curto B, Dell'Orto P, Pasini F, Veronesi G, Spaggiari L, Maisonneuve P, Iannucci A, Terzi A, Lonardoni A, Viale G.
    Int J Cancer; 2005 Jan 01; 113(1):101-8. PubMed ID: 15386424
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer.
    Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, Mossetti C, Ardissone F, Lausi P, Scagliotti GV.
    Ann Oncol; 2004 Jan 01; 15(1):28-32. PubMed ID: 14679115
    [Abstract] [Full Text] [Related]

  • 7. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicoló G, Perdelli L, Stampino CG, Rosso R, Puntoni R.
    Cancer; 2001 Oct 01; 92(7):1896-904. PubMed ID: 11745263
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S, Nuyttens JJ, Maat AP, Birim Ö, Aerts JG, Bogers AJ, Takkenberg JJ.
    Ann Surg Oncol; 2015 Jan 01; 22(1):316-23. PubMed ID: 24962941
    [Abstract] [Full Text] [Related]

  • 11. Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.
    Osarogiagbon RU, Lin CC, Smeltzer MP, Jemal A.
    J Thorac Oncol; 2016 Jan 01; 11(1):e5-16. PubMed ID: 26762752
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mediastinal lymph node examination and survival in resected early-stage non-small-cell lung cancer in the surveillance, epidemiology, and end results database.
    Osarogiagbon RU, Yu X.
    J Thorac Oncol; 2012 Dec 01; 7(12):1798-1806. PubMed ID: 23154551
    [Abstract] [Full Text] [Related]

  • 14. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C, Dong W, Su B, Liu Q, Du J.
    J Thorac Oncol; 2013 Apr 01; 8(4):429-35. PubMed ID: 23486264
    [Abstract] [Full Text] [Related]

  • 15. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
    Sakurai H, Asamura H, Goya T, Eguchi K, Nakanishi Y, Sawabata N, Okumura M, Miyaoka E, Fujii Y, Japanese Joint Committee for Lung Cancer Registration.
    J Thorac Oncol; 2010 Oct 01; 5(10):1594-601. PubMed ID: 20736855
    [Abstract] [Full Text] [Related]

  • 16. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival.
    Bréchot JM, Chevret S, Charpentier MC, Appere de Vecchi C, Capron F, Prudent J, Rochemaure J, Chastang C.
    Cancer; 1996 Nov 15; 78(10):2111-8. PubMed ID: 8918404
    [Abstract] [Full Text] [Related]

  • 17. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
    Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn PA, Varella-Garcia M, Hirsch FR.
    J Clin Oncol; 2010 May 01; 28(13):2174-80. PubMed ID: 20351332
    [Abstract] [Full Text] [Related]

  • 18. Node-negative non-small cell lung cancer: pathological staging and survival in 1765 consecutive cases.
    Robinson BM, Kennedy C, McLean J, McCaughan BC.
    J Thorac Oncol; 2011 Oct 01; 6(10):1691-6. PubMed ID: 21869717
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II.
    Toffalorio F, Radice D, Spaggiari L, Sinno V, Barberis M, Spitaleri G, Giovannini M, Delmonte A, Catania C, Noberasco C, Brambilla D, de Braud F, Veronesi G, Solli P, De Pas T.
    J Thorac Oncol; 2012 Jul 01; 7(7):1124-30. PubMed ID: 22610258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.